ATM Human shRNA Lentiviral Particle (Locus ID 472)

CAT#: TL320267V

ATM - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

Product Images

GFP signal was observed under microscope at 48 hours after transduction of [TL320267C] virus into HEK293 cells. [TL320267C] virus was prepared using lenti-shRNA [TL320267C] and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL320267D] virus into HEK293 cells. [TL320267D] virus was prepared using lenti-shRNA [TL320267D] and TR30037 packaging kit.

Specifications

Product Data

• Locus ID: 472
• Synonyms: AT1; ATA; ATC; ATD; ATDC; ATE; TEL1; TELO1
• Vector: pGFP-C-shLenti
• Format: Lentiviral particles
• RefSeq: BC007023, NM_000051, NM_138292, NM_138293, NM_001351834, NM_001351835, NM_001351836, NM_138292.1, NM_138292.2, NM_138292.3, NM_000051.3, BC022306, BC022307, BC061584, BC137169, BC152385, BC152389, NM_000051.4
• UniProt ID: Q13315
• Summary: The protein encoded by this gene belongs to the PI3/PI4-kinase family. This protein is an important cell cycle checkpoint kinase that phosphorylates; thus, it functions as a regulator of a wide variety of downstream proteins, including tumor suppressor proteins p53 and BRCA1, checkpoint kinase CHK2, checkpoint proteins RAD17 and RAD9, and DNA repair protein NBS1. This protein and the closely related kinase ATR are thought to be master controllers of cell cycle checkpoint signaling pathways that are required for cell response to DNA damage and for genome stability. Mutations in this gene are associated with ataxia telangiectasia, an autosomal recessive disorder. [provided by RefSeq, Aug 2010]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).